Turan Eray Seven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Turan Eray Seven has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Banu Doğan Gün
Department of Pathology, Zonguldak Bülent Ecevit University Faculty of Medicine, Kozlu, Zonguldak, 67639, Türkiye
1 shared publication - Başak Güzelyüz1 shared publication
Berrak Güven
Department of Medical Biochemistry, Zonguldak Bülent Ecevit University Medical School, Zonguldak, Turkey
1 shared publication- Betul Guzelyuz
AFŞİN DEVLET HASTANESİ, GENEL CERRAHİ KLİNİĞİ
1 shared publication - Ergin Erginöz
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
1 shared publication Fürüzan Köktürk
Department of Biostatistics, Zonguldak Bülent Ecevit University Medical School, Zonguldak, Turkey
1 shared publication
Latest Publications
- 24 February 2026
- Published by MediHealth Academy in Journal of Comprehensive Surgery
- Vol. 4 (1) , 1-4
Incidence of malignancy in appendectomy specimens: a three-year retrospective analysis
Aims: Appendectomy is one of the most frequently performed surgical procedures for acute abdominal pain. Appendectomy specimens submitted for pathology often show inflammatory changes, but a small percentage of incidental neoplasms can also be detected. Methods: This study included all patients who underwent appendectomy at our institution between August 2022 and August 2025. All appendix specimens removed, regardless of the indication for surgery, were included. Pathology reports were retrieved from the electronic archive and combined to identify each patient individually. Results: A total of 1168 appendectomy cases were included in the study. The patient ages ranged from 7 to 84 years. The median age was 33 (IQR: 24–42) years, and the mean age was 34.6 ± 12.5 years. 690 patients (59.1%) were male, 477 patients (40.8%) were female; gender information was not available for 1 patient. A total of 3 malignant cases were identified. Malignancy subtypes were recorded according to morphology codes as carcinoid tumor/NET (8240/3) and unspecified malignant neoplasia (8000/3). Additionally, 4 cases were reported as low-grade appendiceal mucinous neoplasm (LAMN). The ages of the LAMN cases ranged from 35 to 65 years, with two patients being male and two being female. Conclusion: This study demonstrated that the incidence of malignancy in appendectomies is low, but different histological types, although rare, can be observed, which can alter clinical management. In addition to malignant subtypes such as neuroendocrine tumors and adenocarcinoma, LAMN cases should be carefully reported as a separate category. The fact that LAMNs can lead to complications such as pseudomyxoma peritonei increases the clinical importance of these lesions. The obtained data highlight the necessity of detailed histopathological examination of every appendectomy specimen. Furthermore, contributing current incidence data from our country to the literature may help both standardize pathological reporting and determine postoperative follow-up strategies.
- 24 February 2026
- Published by MediHealth Academy in Journal of Comprehensive Surgery
- Vol. 4 (1) , 1-4
Incidence of malignancy in appendectomy specimens: a three-year retrospective analysis
Aims: Appendectomy is one of the most frequently performed surgical procedures for acute abdominal pain. Appendectomy specimens submitted for pathology often show inflammatory changes, but a small percentage of incidental neoplasms can also be detected. Methods: This study included all patients who underwent appendectomy at our institution between August 2022 and August 2025. All appendix specimens removed, regardless of the indication for surgery, were included. Pathology reports were retrieved from the electronic archive and combined to identify each patient individually. Results: A total of 1168 appendectomy cases were included in the study. The patient ages ranged from 7 to 84 years. The median age was 33 (IQR: 24–42) years, and the mean age was 34.6 ± 12.5 years. 690 patients (59.1%) were male, 477 patients (40.8%) were female; gender information was not available for 1 patient. A total of 3 malignant cases were identified. Malignancy subtypes were recorded according to morphology codes as carcinoid tumor/NET (8240/3) and unspecified malignant neoplasia (8000/3). Additionally, 4 cases were reported as low-grade appendiceal mucinous neoplasm (LAMN). The ages of the LAMN cases ranged from 35 to 65 years, with two patients being male and two being female. Conclusion: This study demonstrated that the incidence of malignancy in appendectomies is low, but different histological types, although rare, can be observed, which can alter clinical management. In addition to malignant subtypes such as neuroendocrine tumors and adenocarcinoma, LAMN cases should be carefully reported as a separate category. The fact that LAMNs can lead to complications such as pseudomyxoma peritonei increases the clinical importance of these lesions. The obtained data highlight the necessity of detailed histopathological examination of every appendectomy specimen. Furthermore, contributing current incidence data from our country to the literature may help both standardize pathological reporting and determine postoperative follow-up strategies.
- Open Access
- 29 November 2025
- Published by MediHealth Academy in Journal of Comprehensive Surgery
- Vol. 3 (4) , 72-77
Evaluation of cytoreductive surgery and the HIPEC approach in peritoneal metastases from Sugarbaker to the present day with current evidence
Peritoneal metastases (PM) are a common clinical entity in gastrointestinal and gynecological malignancies, often characterized by advanced stages and a poor prognosis. The presence of PM, particularly in colorectal and gastric cancers, has historically been associated with short survival and limited treatment options. The inherent peritoneal-plasma barrier and limited drug diffusion to tumor nodules have historically limited the effectiveness of systemic chemotherapy at peritoneal surfaces. This process has been radically altered since the 1980s by the locoregional treatment approach pioneered by Paul H. Sugarbaker. Sugarbaker conceptualized peritoneal surface malignancies as a potentially "local-regional" disease site, exhibiting a different biology than systemic metastases; He defined a treatment paradigm consisting of the removal of macroscopic tumor burden with cytoreductive surgery (CRS) and targeting residual microscopic disease with hyperthermic intraperitoneal chemotherapy (HIPEC). Most reviews in the existing literature address CRS+HIPEC treatment solely from a surgical and chemotherapeutic perspective. This study offers a multidisciplinary perspective by examining the historical framework from Sugarbaker to the present, biomarker-based selection, artificial intelligence-supported patient assessment models, and data standardization initiatives. The idea that peritoneal surface malignancies have a disease biology distinct from systemic metastasis emerged in the 1980s with a conceptual revolution pioneered by Paul H. Sugarbaker. Sugarbaker redefined the peritoneal cavity as a "treatable anatomical compartment." Thus, a locoregional approach has been developed that aims to overcome the limitations of systemic therapy. The combination of CRS (cytoreductive surgery) and HIPEC is an approach that aims to achieve loco-regional control in peritoneal metastases. However, its effectiveness is sensitive to the primary tumor type, tumor burden (PCI), degree of surgical completeness (CC score), the HIPEC protocol used, and center experience. This section summarizes current evidence for peritoneal metastases from colorectal, ovarian, and gastric cancer (CRC-PM, EOC-PM, GC-PM). Current evidence suggests that cytoreductive surgery (CRS) is the strongest prognostic factor in the management of peritoneal metastases, while HIPEC may provide an additional survival advantage in carefully selected cases with appropriate agent, temperature, and duration parameters. However, current data are still limited due to protocol heterogeneity, agent differences, and variability in patient selection criteria. In the future, thanks to the integration of molecular biomarker-based selection strategies, AI-assisted imaging analyses, and international data-sharing networks (e.g., PSOGI, RENAPE), the CRS+HIPEC approach will become much more individualized, predictable, and standardized. This multifaceted advancement holds the potential to optimize not only survival but also treatment safety and quality of life in the treatment of peritoneal metastases.
- 29 November 2025
- Published by MediHealth Academy in Journal of Comprehensive Surgery
- Vol. 3 (4) , 72-77
Open AccessEvaluation of cytoreductive surgery and the HIPEC approach in peritoneal metastases from Sugarbaker to the present day with current evidence
Peritoneal metastases (PM) are a common clinical entity in gastrointestinal and gynecological malignancies, often characterized by advanced stages and a poor prognosis. The presence of PM, particularly in colorectal and gastric cancers, has historically been associated with short survival and limited treatment options. The inherent peritoneal-plasma barrier and limited drug diffusion to tumor nodules have historically limited the effectiveness of systemic chemotherapy at peritoneal surfaces. This process has been radically altered since the 1980s by the locoregional treatment approach pioneered by Paul H. Sugarbaker. Sugarbaker conceptualized peritoneal surface malignancies as a potentially "local-regional" disease site, exhibiting a different biology than systemic metastases; He defined a treatment paradigm consisting of the removal of macroscopic tumor burden with cytoreductive surgery (CRS) and targeting residual microscopic disease with hyperthermic intraperitoneal chemotherapy (HIPEC). Most reviews in the existing literature address CRS+HIPEC treatment solely from a surgical and chemotherapeutic perspective. This study offers a multidisciplinary perspective by examining the historical framework from Sugarbaker to the present, biomarker-based selection, artificial intelligence-supported patient assessment models, and data standardization initiatives. The idea that peritoneal surface malignancies have a disease biology distinct from systemic metastasis emerged in the 1980s with a conceptual revolution pioneered by Paul H. Sugarbaker. Sugarbaker redefined the peritoneal cavity as a "treatable anatomical compartment." Thus, a locoregional approach has been developed that aims to overcome the limitations of systemic therapy. The combination of CRS (cytoreductive surgery) and HIPEC is an approach that aims to achieve loco-regional control in peritoneal metastases. However, its effectiveness is sensitive to the primary tumor type, tumor burden (PCI), degree of surgical completeness (CC score), the HIPEC protocol used, and center experience. This section summarizes current evidence for peritoneal metastases from colorectal, ovarian, and gastric cancer (CRC-PM, EOC-PM, GC-PM). Current evidence suggests that cytoreductive surgery (CRS) is the strongest prognostic factor in the management of peritoneal metastases, while HIPEC may provide an additional survival advantage in carefully selected cases with appropriate agent, temperature, and duration parameters. However, current data are still limited due to protocol heterogeneity, agent differences, and variability in patient selection criteria. In the future, thanks to the integration of molecular biomarker-based selection strategies, AI-assisted imaging analyses, and international data-sharing networks (e.g., PSOGI, RENAPE), the CRS+HIPEC approach will become much more individualized, predictable, and standardized. This multifaceted advancement holds the potential to optimize not only survival but also treatment safety and quality of life in the treatment of peritoneal metastases.
- Open Access
- 3 November 2025
- Published by Academician Publishing
- p. 23-42
Retroperitoneal Sarkomlar ve Tedavi Yaklaşımı
Retroperitoneal Sarkomların Tanımı Retroperitoneal sarkomlar (RPS), mezankimal hücre kökenli, retroperitoneal boşlukta gelişen nadir ve biyolojik olarak heterojen tümörlerdir. Retroperitoneal bölge; böbrekler, büyük damar yapıları, pankreasın bir kısmı, duodenumun üçüncü ve dördüncü kısımları, adrenal bezler ve lenfatik dokular gibi birçok hayati organ ve yapıyı içerir. Bu anatomik yerleşim, RPS'lerin semptom vermeden uzun süre büyümesine imkân tanır. Erken dönemde hastalar sıklıkla asemptomatiktir; tanı çoğunlukla tesadüfi görüntüleme sırasında ya da kitle boyutunun artarak komşu organlara bası semptomları oluşturmasıyla konur
- 3 November 2025
- Published by Academician Publishing
- p. 23-42
Open AccessRetroperitoneal Sarkomlar ve Tedavi Yaklaşımı
Retroperitoneal Sarkomların Tanımı Retroperitoneal sarkomlar (RPS), mezankimal hücre kökenli, retroperitoneal boşlukta gelişen nadir ve biyolojik olarak heterojen tümörlerdir. Retroperitoneal bölge; böbrekler, büyük damar yapıları, pankreasın bir kısmı, duodenumun üçüncü ve dördüncü kısımları, adrenal bezler ve lenfatik dokular gibi birçok hayati organ ve yapıyı içerir. Bu anatomik yerleşim, RPS'lerin semptom vermeden uzun süre büyümesine imkân tanır. Erken dönemde hastalar sıklıkla asemptomatiktir; tanı çoğunlukla tesadüfi görüntüleme sırasında ya da kitle boyutunun artarak komşu organlara bası semptomları oluşturmasıyla konur
- Open Access
- 3 November 2025
- Published by Academician Publishing
- p. 43-66
Kutanöz Melanomun Cerrahi Yönetimi ve Multidisipliner Yaklaşım
Malign melanom, melanosit kökenli, çoğunlukla deri yerleşimli olmakla birlikte mukozalarda ve nadiren oküler bölgede görülebilen agresif
- 3 November 2025
- Published by Academician Publishing
- p. 43-66
Open AccessKutanöz Melanomun Cerrahi Yönetimi ve Multidisipliner Yaklaşım
Malign melanom, melanosit kökenli, çoğunlukla deri yerleşimli olmakla birlikte mukozalarda ve nadiren oküler bölgede görülebilen agresif
- Open Access
- 3 November 2025
- Published by Academician Publishing
Güncel Genel Cerrahi Çalışmaları VIII (AYBAK 2025 Güz)
- 3 November 2025
- Published by Academician Publishing
Open AccessGüncel Genel Cerrahi Çalışmaları VIII (AYBAK 2025 Güz)
- 13 June 2025
- Published by Elsevier in Journal of Surgical Research
- Vol. 312, 37-47
Effects of Levosimendan on Anastomotic Healing in an Ischemic Colon Anastomosis Model
- 13 June 2025
- Published by Elsevier in Journal of Surgical Research
- Vol. 312, 37-47
Effects of Levosimendan on Anastomotic Healing in an Ischemic Colon Anastomosis Model
- Open Access
- 1 December 2022
- Published by Galenos Yayinevi in Turkish Journal of Surgery
- Vol. 38 (4) , 413-417
Gardner’s syndrome: Simultaneous diagnosis and treatment in monozygotic twins
Gardner’s syndrome (GS) is a very rare autosomal dominant multisystem disease. Osteomas, skin and soft tissue tumors are present with gastrointestinal polyposis. The polyps have very high malignancy potentials. If prophylactic resection is not performed, colorectal cancer development is inevitable in all patients with GS. Polyposis is usually asymptomatic. Therefore, careful evaluation of extraintestinal findings of the disease is very important for early diagnosis. In this article, diagnosis and treatment of GS are presented in monozygotic twins, which have not been previously described in the literature. The diagnostic process, which started with dental complaints of one case, was carried out in an effective manner and then, prophylactic surgery was performed in twins. This article aimed to make clinicians and dentists attentive for early diagnosis of disease and to review treatment options.
- 1 December 2022
- Published by Galenos Yayinevi in Turkish Journal of Surgery
- Vol. 38 (4) , 413-417
Open AccessGardner’s syndrome: Simultaneous diagnosis and treatment in monozygotic twins
Gardner’s syndrome (GS) is a very rare autosomal dominant multisystem disease. Osteomas, skin and soft tissue tumors are present with gastrointestinal polyposis. The polyps have very high malignancy potentials. If prophylactic resection is not performed, colorectal cancer development is inevitable in all patients with GS. Polyposis is usually asymptomatic. Therefore, careful evaluation of extraintestinal findings of the disease is very important for early diagnosis. In this article, diagnosis and treatment of GS are presented in monozygotic twins, which have not been previously described in the literature. The diagnostic process, which started with dental complaints of one case, was carried out in an effective manner and then, prophylactic surgery was performed in twins. This article aimed to make clinicians and dentists attentive for early diagnosis of disease and to review treatment options.